33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Lamanna, N.; Flinn, I.; Barrientos, J. C.; Kambhampati, S.; Cheson, B. D.; Barr, P. M.; Pagel, J. M.; Reeves, J. A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib
    Meeting Abstract

    Mauro, M. J.; Lang, F.; Kim, D. W.; Cortes, J. E.; Hughes, T. P.; Hochhaus, A.; Minami, H.; Boquimpani, C.; Minami, Y.; DeAngelo, D. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Management and outcomes of 222 CLL patients (pts) treated with venetoclax (VEN) in the real world
    Meeting Abstract

    Nabhan, C.; Klink, A.; Samp, J.; Pauff, J. M.; Nielsen, J.; Meissner, B.; Keim, H.; Kennard, K.; Mato, A. R.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Predicting Oncotype DX scores using clinicopathologic features: A report from the National Cancer Database
    Meeting Abstract

    Pesce, C.; Kuchta, K.; Erdogan, B.; Wang, C.; Yao, K.; El-Tamer, M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06)
    Meeting Abstract

    Risi, E.; Biagioni, C.; Benelli, M.; Migliaccio, I.; McCartney, A.; Bonechi, M.; Guarducci, C.; Hilbers, F.; Di Cosimo, S.; Baselga, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial
    Meeting Abstract

    Jhaveri, K. L.; Makker, V.; Wang, X. V.; Chen, A. P.; Flaherty, K.; Conley, B. A.; O'Dwyer, P. J.; Williams, P. M.; Hamilton, S. R.; Harris, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A US-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts)
    Meeting Abstract

    Koffman, B.; Dennison, B.; Kennard, K.; Byrd, J. C.; Pagel, J. M.; Davids, M. S.; Nabhan, C.; Kay, N. E.; Siddiqi, T.; Brander, D. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study
    Meeting Abstract

    Liu, M. C.; Maddala, T.; Aravanis, A.; Hubbell, E.; Beausang, J. F.; Filippova, D.; Gross, S.; Jamshidi, A.; Kurtzman, K.; Shen, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer
    Meeting Abstract

    Lyons, T.; Gucalp, A.; Arumov, A.; Patil, S.; Edelweiss, M.; Gorsky, M.; Troso-Sandoval, T. A.; Bromberg, J.; Sanford, R. A.; Iyengar, N. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay
    Meeting Abstract

    Gradishar, W. J.; Robson, M. E.; Flake, D. D.; Schwartzberg, L. S.; Sharma, P.; Soliman, H. H.; Magliocco, A. M.; Brown, K.; Wehnelt, S.; Gutin, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save